BP43131, a phase 1 dose escalation study: CD19 targeted CD28 costimulatory agonist (RO7443904) combined with glofitamab shows promising efficacy in patients with relapsed/refractory aggressive B-NHL Meeting Abstract
| Authors: | Dickinson, M. J.; Hutchings, M.; Morschhauser, F.; Carlo-Stella, C.; Falchi, L.; Caimi, P. F.; Dimier, N.; Smith, L.; Whayman, M.; Sam, J.; Keelara, A.; Korfi, K.; Jamois, C.; Gallien, J.; Martin, N.; Quetglas, I. M.; Hinton, H.; Prieto, I.; Michielin, F.; Lechner, K.; Gritti, G. |
| Abstract Title: | BP43131, a phase 1 dose escalation study: CD19 targeted CD28 costimulatory agonist (RO7443904) combined with glofitamab shows promising efficacy in patients with relapsed/refractory aggressive B-NHL |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 3123 |
| Language: | English |
| ACCESSION: | WOS:001412771300023 |
| DOI: | 10.1182/blood-2024-205544 |
| PROVIDER: | wos |
| Notes: | Source: Wos |
